NCI logo

NEO-CONCEPT INTL GROUP HLD-A

NCINASDAQ
πŸ† #5009 by market capUS Equity
$4.02β–Ό $0.22 (βˆ’5.30%)
Market closed Β· at close
πŸ””
Track NCI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.3%
7dβ–Ό 26.0%
14dβ–Ό 6.9%
30dβ–Ό 36.6%
ytdβ–Ό 94.4%
1yβ–Ό 94.3%
🏦Market Cap
$4M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-41.8%
Declining
πŸ“ŠGross Margin
34.2%
Moderate
πŸ’΅FCF Margin
-8.2%
Thin
βš–οΈP/S Ratio
0.1x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$3.71 – $4.09
52-Week Range
$2.00 – $883.84
Volume (shares)
6,271
Avg Volume (shares)
β€”
Shares Outstanding
1.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$137M
Last Q Revenue
$56M
P/E Ratio
-0.7
P/S Ratio
0.1x
EPS (TTM)
$-39.77
Dividend Yield
0.00%
Dilution (1yr)
βˆ’80.0%
NCI logo

NEO-CONCEPT INTL GROUP HLD-A

NCI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$137Mβ–Ό βˆ’41.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.9%β–² +76.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2Mβ–Ό βˆ’84.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$17Mβ–Ό βˆ’192.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64Kβ–Ό βˆ’80.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$44Mβ–² +$16M YoY
StockOtter Β· stockotter.space

About NEO-CONCEPT INTL GROUP HLD-A

Neo-Concept International Group Holdings Limited, established in 2021 and headquartered in Kwun Tong, Hong Kong, operates as a comprehensive provider of apparel solutions. This subsidiary of Neo-concept (BVI) Limited offers a wide spectrum of services throughout the clothing supply chain. These services include analyzing market trends, designing and developing products, procuring raw materials, overseeing production and quality assurance, and managing logistics. Furthermore, the company sells knitwear and other garments under its "les 100 ciels" label. Its primary customer base comprises brand owners, clothing sourcing agencies, and online fashion retailers, mainly situated in North America, the United Kingdom, and across Europe.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·2d ago

Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium

REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maxi

GlobeNewsWireΒ·4d ago

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months

GlobeNewsWireΒ·4d ago

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium

SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (β€œOlema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies

GlobeNewsWireΒ·18d ago

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (β€œAcrivon” or β€œAcrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines u

GlobeNewsWireΒ·20d ago

Neo-Concept International Announces Share Consolidation

HONG KONG, Nov. 02, 2026 (GLOBE NEWSWIRE) -- On October 29, 2026, Neo-Concept International Group Holdings Ltd (the β€œCompany”) held the Company's Extraordinary General Meeting (the β€œEGM”) , amongst which a share consolid

GlobeNewsWireΒ·24d ago

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-